Aptose Biosciences Inc. (APTO)
USD 1.71
(0.0%)
USD 1.71
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 621 Thousand USD | -38.02% |
| 2022 | 1 Million USD | 771.3% |
| 2021 | 115 Thousand USD | -78.5% |
| 2020 | 535 Thousand USD | -47.08% |
| 2019 | 1.01 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | -100.0% |
| 2014 | 486.24 Thousand USD | -0.07% |
| 2013 | 486.6 Thousand USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | -100.0% |
| 2010 | 2.84 Million USD | 0.0% |
| 2009 | 2.84 Million USD | -82.08% |
| 2008 | 15.87 Million USD | 23.9% |
| 2007 | 12.81 Million USD | 14.81% |
| 2006 | 11.16 Million USD | 11.7% |
| 2005 | 9.99 Million USD | 22.79% |
| 2004 | 8.13 Million USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 520 Thousand USD | 0.0% |
| 2024 Q2 | 414 Thousand USD | 0.0% |
| 2023 Q1 | 918 Thousand USD | -8.38% |
| 2023 Q2 | 817 Thousand USD | -11.0% |
| 2023 FY | 621 Thousand USD | -38.02% |
| 2023 Q3 | 720 Thousand USD | -11.87% |
| 2023 Q4 | 621 Thousand USD | -13.75% |
| 2022 Q1 | 10 Thousand USD | -91.3% |
| 2022 FY | 1 Million USD | 771.3% |
| 2022 Q4 | 1 Million USD | 100100.0% |
| 2022 Q3 | 1000.00 USD | -66.67% |
| 2022 Q2 | 3000.00 USD | -70.0% |
| 2021 Q1 | 420 Thousand USD | -21.5% |
| 2021 Q4 | 115 Thousand USD | -47.25% |
| 2021 Q3 | 218 Thousand USD | -32.09% |
| 2021 FY | 115 Thousand USD | -78.5% |
| 2021 Q2 | 321 Thousand USD | -23.57% |
| 2020 Q4 | 535 Thousand USD | -18.69% |
| 2020 FY | 535 Thousand USD | -47.08% |
| 2020 Q3 | 658 Thousand USD | -15.21% |
| 2020 Q1 | 894 Thousand USD | -11.57% |
| 2020 Q2 | 776 Thousand USD | -13.2% |
| 2019 FY | 1.01 Million USD | 0.0% |
| 2019 Q4 | 1.01 Million USD | -10.05% |
| 2019 Q1 | 1.32 Million USD | 0.0% |
| 2019 Q3 | 1.12 Million USD | -7.49% |
| 2019 Q2 | 1.21 Million USD | -8.09% |
| 2018 FY | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 FY | - USD | -100.0% |
| 2014 Q2 | 486.6 Thousand USD | -18.58% |
| 2014 Q4 | 486.24 Thousand USD | 80937.73% |
| 2014 Q3 | 600.02 USD | -99.88% |
| 2014 Q1 | 597.66 Thousand USD | -2.83% |
| 2014 FY | 486.24 Thousand USD | -0.07% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | 486.6 Thousand USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | 615.06 Thousand USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2011 FY | - USD | -100.0% |
| 2011 Q2 | 2.84 Million USD | 0.0% |
| 2011 Q1 | - USD | -100.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | -100.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | 2.84 Million USD | 0.0% |
| 2010 Q2 | 2.84 Million USD | 0.0% |
| 2010 Q4 | 2.84 Million USD | 0.0% |
| 2010 Q3 | - USD | -100.0% |
| 2009 Q3 | - USD | -100.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | 2.84 Million USD | -82.08% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | 15.87 Million USD | 0.0% |
| 2008 FY | 15.87 Million USD | 23.9% |
| 2008 Q2 | 12.81 Million USD | 0.55% |
| 2008 Q3 | 12.34 Million USD | -3.63% |
| 2008 Q4 | - USD | -100.0% |
| 2008 Q1 | 12.74 Million USD | 4.78% |
| 2007 Q2 | 11.16 Million USD | 11.81% |
| 2007 Q4 | 12.16 Million USD | 8.31% |
| 2007 FY | 12.81 Million USD | 14.81% |
| 2007 Q1 | 9.98 Million USD | -0.46% |
| 2007 Q3 | 11.23 Million USD | 0.62% |
| 2006 Q4 | 10.02 Million USD | -1.2% |
| 2006 FY | 11.16 Million USD | 11.7% |
| 2006 Q3 | 10.15 Million USD | 1.59% |
| 2006 Q2 | 9.99 Million USD | 5.47% |
| 2006 Q1 | 9.47 Million USD | 0.0% |
| 2005 Q3 | 8.75 Million USD | 7.57% |
| 2005 Q2 | 8.13 Million USD | 51.49% |
| 2005 Q1 | 5.37 Million USD | 103.93% |
| 2005 FY | 9.99 Million USD | 22.79% |
| 2005 Q4 | - USD | -100.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 FY | 8.13 Million USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q4 | 2.63 Million USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Caribou Biosciences, Inc. | 25.9 Million USD | 97.603% |
| Inhibikase Therapeutics, Inc. | 90.12 Thousand USD | -589.051% |
| Alaunos Therapeutics, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| Phathom Pharmaceuticals, Inc. | 138.3 Million USD | 99.551% |
| C4 Therapeutics, Inc. | 65.75 Million USD | 99.056% |
| Agenus Inc. | 137.32 Million USD | 99.548% |
| Fortress Biotech, Inc. | 60.85 Million USD | 98.98% |
| GlycoMimetics, Inc. | 66.84 Thousand USD | -829.029% |
| Novavax, Inc. | 168.01 Million USD | 99.63% |
| Keros Therapeutics, Inc. | 13.43 Million USD | 95.379% |
| Eton Pharmaceuticals, Inc. | 22 Thousand USD | -2722.727% |
| CARGO Therapeutics, Inc. Common Stock | 26.26 Million USD | 97.635% |
| Entrada Therapeutics, Inc. | 60.32 Million USD | 98.971% |
| Akebia Therapeutics, Inc. | 71.19 Million USD | 99.128% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 99.973% |
| AlloVir, Inc. | 16.64 Million USD | 96.27% |
| Aptorum Group Limited | 3.05 Million USD | 79.696% |
| Ardelyx, Inc. | 51.54 Million USD | 98.795% |
| Bicycle Therapeutics plc | 40.08 Million USD | 98.451% |
| BioXcel Therapeutics, Inc. | 100.59 Million USD | 99.383% |
| Chimerix, Inc. | 125 Thousand USD | -396.8% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | 80.825% |
| CRISPR Therapeutics AG | 223 Million USD | 99.722% |
| Clearside Biomedical, Inc. | 41.98 Million USD | 98.521% |
| Precision BioSciences, Inc. | 7.72 Million USD | 91.959% |
| Dyadic International, Inc. | 88.87 Thousand USD | -598.773% |
| Elevation Oncology, Inc. | 30.13 Million USD | 97.939% |
| Fortress Biotech, Inc. | 60.85 Million USD | 98.98% |
| GT Biopharma, Inc. | - USD | -Infinity% |
| Alkermes plc | 287.73 Million USD | 99.784% |
| Immix Biopharma, Inc. | - USD | -Infinity% |
| Innoviva, Inc. | 446.23 Million USD | 99.861% |
| IO Biotech, Inc. | 1.83 Million USD | 66.232% |
| Jaguar Health, Inc. | 30.99 Million USD | 97.996% |
| Ligand Pharmaceuticals Incorporated | 5.75 Million USD | 89.209% |
| ContextLogic Inc. | 6 Million USD | 89.65% |
| AbCellera Biologics Inc. | 71.22 Million USD | 99.128% |
| Lantern Pharma Inc. | 61.49 Thousand USD | -909.822% |
| Kintara Therapeutics, Inc. | - USD | -Infinity% |
| Arrowhead Pharmaceuticals, Inc. | 104.6 Million USD | 99.406% |
| Madrigal Pharmaceuticals, Inc. | 115.48 Million USD | 99.462% |
| MEI Pharma, Inc. | - USD | -Infinity% |
| Barinthus Biotherapeutics plc | 11.19 Million USD | 94.451% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Marinus Pharmaceuticals, Inc. | 95.18 Million USD | 99.348% |
| NextCure, Inc. | 5.94 Million USD | 89.561% |
| HOOKIPA Pharma Inc. | 3.8 Million USD | 83.662% |
| ChromaDex Corporation | 2.57 Million USD | 75.883% |
| IDEAYA Biosciences, Inc. | 1.12 Million USD | 44.8% |
| Incyte Corporation | 29.16 Million USD | 97.871% |
| Opthea Limited | 200.53 Million USD | 99.69% |
| MiMedx Group, Inc. | 48.09 Million USD | 98.709% |
| Outlook Therapeutics, Inc. | - USD | -Infinity% |
| Aadi Bioscience, Inc. | 833 Thousand USD | 25.45% |
| Psyence Biomedical Ltd. | - USD | -Infinity% |
| Vaxcyte, Inc. | 22.11 Million USD | 97.191% |
| PDS Biotechnology Corporation | 19.5 Million USD | 96.816% |
| Pharming Group N.V. | 166.1 Million USD | 99.626% |
| Pieris Pharmaceuticals, Inc. | - USD | -Infinity% |
| Onconetix, Inc. | 118.85 Thousand USD | -422.477% |
| Acelyrin, Inc. | 1.19 Million USD | 47.99% |
| PureTech Health plc | 18.25 Million USD | 96.597% |
| Pyxis Oncology, Inc. | 20.09 Million USD | 96.91% |
| Avidity Biosciences, Inc. | 6.21 Million USD | 90.005% |
| TransCode Therapeutics, Inc. | 38.29 Thousand USD | -1521.791% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| ESSA Pharma Inc. | - USD | -Infinity% |
| Rigel Pharmaceuticals, Inc. | 52.65 Million USD | 98.821% |
| Ocuphire Pharma, Inc. | - USD | -Infinity% |
| Seer, Inc. | 25.96 Million USD | 97.608% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | 98.147% |
| SELLAS Life Sciences Group, Inc. | 460 Thousand USD | -35.0% |
| Sol-Gel Technologies Ltd. | 1.2 Million USD | 48.507% |
| Salarius Pharmaceuticals, Inc. | - USD | -Infinity% |
| Summit Therapeutics Inc. | 103.29 Million USD | 99.399% |
| Sensei Biotherapeutics, Inc. | 3.76 Million USD | 83.523% |
| Senti Biosciences, Inc. | 33.53 Million USD | 98.148% |
| ImmuCell Corporation | 10.54 Million USD | 94.108% |
| Syros Pharmaceuticals, Inc. | 34.55 Million USD | 98.203% |
| Janux Therapeutics, Inc. | 23.02 Million USD | 97.303% |
| Precigen, Inc. | 5.89 Million USD | 89.466% |
| Longboard Pharmaceuticals, Inc. | - USD | -Infinity% |
| Oncternal Therapeutics, Inc. | 145 Thousand USD | -328.276% |
| Stoke Therapeutics, Inc. | 4.77 Million USD | 86.989% |
| Xeris Biopharma Holdings, Inc. | 190.93 Million USD | 99.675% |
| Telomir Pharmaceuticals, Inc. Common Stock | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 99.405% |
| Verrica Pharmaceuticals Inc. | 42.87 Million USD | 98.552% |
| VistaGen Therapeutics, Inc. | 1.57 Million USD | 60.446% |
| VYNE Therapeutics Inc. | 99 Thousand USD | -527.273% |
| Windtree Therapeutics, Inc. | 15 Million USD | 95.86% |
| Wave Life Sciences Ltd. | 25.4 Million USD | 97.556% |
| Fate Therapeutics, Inc. | 97.36 Million USD | 99.362% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | 15.164% |
| Inhibrx Biosciences, Inc. | 206.96 Million USD | 99.7% |
| Catalyst Pharmaceuticals, Inc. | 3.18 Million USD | 80.521% |
| Orchestra BioMed Holdings, Inc. | 1.03 Million USD | 40.173% |
| Alzamend Neuro, Inc. | - USD | -Infinity% |
| Rocket Pharmaceuticals, Inc. | 22.32 Million USD | 97.218% |
| ZyVersa Therapeutics, Inc. | - USD | -Infinity% |
| Soligenix, Inc. | 1.01 Million USD | 38.572% |
| Century Therapeutics, Inc. | 46.65 Million USD | 98.669% |
| Kura Oncology, Inc. | 9.33 Million USD | 93.345% |
| TScan Therapeutics, Inc. | 26.7 Million USD | 97.674% |
| Intensity Therapeutics, Inc. | 138 Thousand USD | -350.0% |
| Ocean Biomedical, Inc. | - USD | -Infinity% |
| CytomX Therapeutics, Inc. | 9.38 Million USD | 93.383% |
| Autolus Therapeutics plc | 47.91 Million USD | 98.704% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| EyePoint Pharmaceuticals, Inc. | 4.9 Million USD | 87.342% |
| Eterna Therapeutics Inc. | 6.77 Million USD | 90.831% |
| Adaptive Biotechnologies Corporation | 130.66 Million USD | 99.525% |
| GRI Bio, Inc. | - USD | -Infinity% |
| Xenetic Biosciences, Inc. | - USD | -Infinity% |
| Tenaya Therapeutics, Inc. | 8.1 Million USD | 92.338% |
| IGM Biosciences, Inc. | 34.67 Million USD | 98.209% |
| INmune Bio, Inc. | 397 Thousand USD | -56.423% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 99.643% |
| SAB Biotherapeutics, Inc. | 4.05 Million USD | 84.683% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Entero Therapeutics, Inc. | 146.94 Thousand USD | -322.596% |
| Milestone Pharmaceuticals Inc. | 49.77 Million USD | 98.752% |
| X4 Pharmaceuticals, Inc. | 54.57 Million USD | 98.862% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 98.641% |
| Coherus BioSciences, Inc. | 473.36 Million USD | 99.869% |
| Verastem, Inc. | 40.08 Million USD | 98.451% |
| Abeona Therapeutics Inc. | 4.4 Million USD | 85.893% |
| Pliant Therapeutics, Inc. | 10.05 Million USD | 93.823% |
| Tonix Pharmaceuticals Holding Corp. | 6.56 Million USD | 90.535% |
| Histogen Inc. | 4.38 Million USD | 85.835% |
| Aprea Therapeutics, Inc. | - USD | -Infinity% |
| Surrozen, Inc. | 882 Thousand USD | 29.592% |
| Organovo Holdings, Inc. | 888 Thousand USD | 30.068% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Ovid Therapeutics Inc. | 30 Million USD | 97.93% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | 85.193% |
| CASI Pharmaceuticals, Inc. | 18.89 Million USD | 96.713% |
| Cadrenal Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Centessa Pharmaceuticals plc | 75.7 Million USD | 99.18% |
| Hepion Pharmaceuticals, Inc. | 93.1 Thousand USD | -566.996% |
| Arcturus Therapeutics Holdings Inc. | 25.9 Million USD | 97.603% |
| BioRestorative Therapies, Inc. | - USD | -Infinity% |
| Apollomics, Inc. | 267 Thousand USD | -132.584% |
| Amarin Corporation plc | 8.73 Million USD | 92.892% |
| Mesoblast Limited | 100.48 Million USD | 99.382% |
| Turnstone Biologics Corp. | 1.18 Million USD | 47.771% |
| Kymera Therapeutics, Inc. | 78.32 Million USD | 99.207% |
| Synaptogenix, Inc. | - USD | -Infinity% |
| Tiziana Life Sciences Ltd | 109 Thousand USD | -469.725% |
| Aurinia Pharmaceuticals Inc. | 82 Million USD | 99.243% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Exelixis, Inc. | 189.94 Million USD | 99.673% |
| Better Therapeutics, Inc. | 10.34 Million USD | 93.999% |
| Nurix Therapeutics, Inc. | 23.12 Million USD | 97.315% |
| Apellis Pharmaceuticals, Inc. | 93.03 Million USD | 99.332% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | 51.935% |
| Gritstone bio, Inc. | 40.14 Million USD | 98.453% |
| Jasper Therapeutics, Inc. | 1.81 Million USD | 65.766% |
| TNF Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avid Bioservices, Inc. | 153.59 Million USD | 99.596% |
| Insmed Incorporated | 1.19 Billion USD | 99.948% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| MediWound Ltd. | 6.35 Million USD | 90.22% |
| OmniAb, Inc. | 22.07 Million USD | 97.187% |
| Alector, Inc. | 30.45 Million USD | 97.961% |
| Seres Therapeutics, Inc. | 101.54 Million USD | 99.388% |
| Checkpoint Therapeutics, Inc. | - USD | -Infinity% |
| Zai Lab Limited | 8.04 Million USD | 92.283% |
| Revance Therapeutics, Inc. | 426.59 Million USD | 99.854% |
| Aura Biosciences, Inc. | 16.87 Million USD | 96.319% |
| Lyell Immunopharma, Inc. | 56.89 Million USD | 98.908% |
| Immunic, Inc. | 639 Thousand USD | 2.817% |
| Tarsus Pharmaceuticals, Inc. | 29.81 Million USD | 97.917% |
| Veracyte, Inc. | 7.52 Million USD | 91.748% |
| InMed Pharmaceuticals Inc. | 644.86 Million USD | 99.904% |
| FibroGen, Inc. | 89.69 Million USD | 99.308% |
| SeaStar Medical Holding Corporation | 4.33 Million USD | 85.681% |
| Adial Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sonnet BioTherapeutics Holdings, Inc. | 130.86 Thousand USD | -374.542% |
| Jazz Pharmaceuticals plc | 5.1 Billion USD | 99.988% |
| Cyclacel Pharmaceuticals, Inc. | 37 Thousand USD | -1578.378% |
| Amylyx Pharmaceuticals, Inc. | 1.98 Million USD | 68.636% |
| TG Therapeutics, Inc. | 100.11 Million USD | 99.38% |
| Galecto, Inc. | 66 Thousand USD | -840.909% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -356.618% |
| Fortrea Holdings Inc. | 1.63 Billion USD | 99.962% |
| KalVista Pharmaceuticals, Inc. | 6.01 Million USD | 89.676% |
| Aptevo Therapeutics Inc. | 5.39 Million USD | 88.494% |
| XBiotech Inc. | - USD | -Infinity% |
| Jasper Therapeutics, Inc. | 1.81 Million USD | 65.766% |
| Lyra Therapeutics, Inc. | 21.44 Million USD | 97.104% |
| Foghorn Therapeutics Inc. | 36.55 Million USD | 98.301% |
| Y-mAbs Therapeutics, Inc. | 517 Thousand USD | -20.116% |
| Theravance Biopharma, Inc. | 45.23 Million USD | 98.627% |
| Ultragenyx Pharmaceutical Inc. | 30.57 Million USD | 97.969% |
| Metagenomi, Inc. Common Stock | 44.8 Million USD | 98.614% |
| Vaxxinity, Inc. | 13.26 Million USD | 95.317% |
| BioCryst Pharmaceuticals, Inc. | 811.26 Million USD | 99.923% |
| Gain Therapeutics, Inc. | 449.05 Thousand USD | -38.291% |
| Cartesian Therapeutics, Inc. | 8.78 Million USD | 92.934% |
| NexImmune, Inc. | - USD | -Infinity% |
| Creative Medical Technology Holdings, Inc. | - USD | -Infinity% |
| Marker Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.977% |
| Chemomab Therapeutics Ltd. | 316 Thousand USD | -96.519% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| RAPT Therapeutics, Inc. | 4.45 Million USD | 86.07% |
| Ainos, Inc. | 5.92 Million USD | 89.513% |
| Pluri Inc. | 29.05 Million USD | 97.863% |
| Prothena Corporation plc | 10.72 Million USD | 94.208% |
| Adaptimmune Therapeutics plc | 19.85 Million USD | 96.872% |
| Celularity Inc. | 26.17 Million USD | 97.628% |
| Rallybio Corporation | 173 Thousand USD | -258.96% |
| Cue Biopharma, Inc. | 4.2 Million USD | 85.221% |
| MeiraGTx Holdings plc | 72.11 Million USD | 99.139% |
| Omeros Corporation | 329.7 Million USD | 99.812% |
| Humacyte, Inc. | 38.6 Million USD | 98.391% |
| Immunocore Holdings plc | 82.64 Million USD | 99.249% |
| Cocrystal Pharma, Inc. | 1.61 Million USD | 61.5% |
| Cidara Therapeutics, Inc. | 3.57 Million USD | 82.639% |
| Blueprint Medicines Corporation | 610.96 Million USD | 99.898% |
| CalciMedica, Inc. | - USD | -Infinity% |
| Cabaletta Bio, Inc. | 1.45 Million USD | 57.407% |
| Scholar Rock Holding Corporation | 48.68 Million USD | 98.724% |
| Sana Biotechnology, Inc. | 90.9 Million USD | 99.317% |
| Pulmatrix, Inc. | 8.32 Million USD | 92.542% |
| Elicio Therapeutics, Inc. | 6 Million USD | 89.662% |
| Vigil Neuroscience, Inc. | 12.94 Million USD | 95.203% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 99.358% |
| Adlai Nortye Ltd. American Depositary Shares | 469 Thousand USD | -32.409% |
| Cytokinetics, Incorporated | 607.37 Million USD | 99.898% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | 92.855% |
| Nutriband Inc. | 79.82 Thousand USD | -677.942% |
| Protara Therapeutics, Inc. | 4.48 Million USD | 86.151% |
| Vor Biopharma Inc. | 31.83 Million USD | 98.049% |
| Roivant Sciences Ltd. | 477.85 Million USD | 99.87% |
| Evogene Ltd. | 10.65 Million USD | 94.171% |
| ProKidney Corp. | 3.61 Million USD | 82.798% |
| Applied Therapeutics, Inc. | 759 Thousand USD | 18.182% |
| Hoth Therapeutics, Inc. | 26.32 Thousand USD | -2258.885% |
| BridgeBio Pharma, Inc. | 1.73 Billion USD | 99.964% |
| CorMedix Inc. | 517.01 Thousand USD | -20.113% |
| BioLineRx Ltd. | 6.62 Million USD | 90.631% |
| Tango Therapeutics, Inc. | 36.83 Million USD | 98.314% |
| Galectin Therapeutics Inc. | 71.74 Million USD | 99.134% |
| Atai Life Sciences N.V. | 15.21 Million USD | 95.917% |
| Renovaro Biosciences Inc. | 842.38 Thousand USD | 26.281% |
| Aerovate Therapeutics, Inc. | 255 Thousand USD | -143.529% |
| Zentalis Pharmaceuticals, Inc. | 43.15 Million USD | 98.561% |
| Sagimet Biosciences Inc. | - USD | -Infinity% |
| MediciNova, Inc. | 410.66 Thousand USD | -51.22% |
| Praxis Precision Medicines, Inc. | 1.36 Million USD | 54.638% |
| Cardio Diagnostics Holdings, Inc. | 663.09 Thousand USD | 6.349% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 99.651% |
| Biomea Fusion, Inc. | 7.83 Million USD | 92.069% |
| PTC Therapeutics, Inc. | 284.21 Million USD | 99.782% |
| Mereo BioPharma Group plc | 5.3 Million USD | 88.283% |
| Cullinan Oncology, Inc. | 2.15 Million USD | 71.116% |
| Syndax Pharmaceuticals, Inc. | 588 Thousand USD | -5.612% |
| Absci Corporation | 4.66 Million USD | 86.674% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| 4D Molecular Therapeutics, Inc. | 11.52 Million USD | 94.61% |
| Dyne Therapeutics, Inc. | 22.69 Million USD | 97.264% |
| Kiniksa Pharmaceuticals, Ltd. | 10 Million USD | 93.793% |
| Ventyx Biosciences, Inc. | 11.5 Million USD | 94.602% |
| Allakos Inc. | 38.21 Million USD | 98.375% |
| Imunon, Inc. | 1.13 Million USD | 45.493% |
| Fulcrum Therapeutics, Inc. | 8.62 Million USD | 92.803% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| BioAtla, Inc. | 836 Thousand USD | 25.718% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -6110.0% |
| Allogene Therapeutics, Inc. | 88.34 Million USD | 99.297% |
| Larimar Therapeutics, Inc. | 4.7 Million USD | 86.812% |
| XOMA Corporation | 118.51 Million USD | 99.476% |
| Kezar Life Sciences, Inc. | 10.06 Million USD | 93.833% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 98.325% |
| aTyr Pharma, Inc. | 13.76 Million USD | 95.489% |
| Aligos Therapeutics, Inc. | 7.89 Million USD | 92.138% |
| Akero Therapeutics, Inc. | 24.96 Million USD | 97.512% |
| Viridian Therapeutics, Inc. | 20.2 Million USD | 96.927% |
| Eliem Therapeutics, Inc. | 15 Thousand USD | -4040.0% |
| EyeGate Pharmaceuticals, Inc. | 278.19 Thousand USD | -123.229% |
| Akari Therapeutics, Plc | - USD | -Infinity% |
| Tevogen Bio Holdings Inc. | 14.45 Million USD | 95.704% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.959% |
| Lexaria Bioscience Corp. | 136.17 Thousand USD | -356.038% |
| UroGen Pharma Ltd. | 98.55 Million USD | 99.37% |
| Sutro Biopharma, Inc. | 149.11 Million USD | 99.584% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | 96.743% |
| Entera Bio Ltd. | 256 Thousand USD | -142.578% |
| GH Research PLC | 631 Thousand USD | 1.585% |
| Lisata Therapeutics, Inc. | 137.00 USD | -453184.672% |
| Reneo Pharmaceuticals, Inc. | 642 Thousand USD | 3.271% |
| Xencor, Inc. | 14.64 Million USD | 95.759% |
| 60 Degrees Pharmaceuticals, Inc. | 150.25 Thousand USD | -313.308% |
| Replimune Group, Inc. | 71.99 Million USD | 99.137% |
| Coeptis Therapeutics Holdings, Inc. | 150 Thousand USD | -314.0% |
| Vanda Pharmaceuticals Inc. | 7 Million USD | 91.136% |
| Lexaria Bioscience Corp. | 136.17 Thousand USD | -356.038% |
| Portage Biotech Inc. | 7000.00 USD | -8771.429% |
| Cardio Diagnostics Holdings, Inc. | 663.09 Thousand USD | 6.349% |
| Olema Pharmaceuticals, Inc. | 1.42 Million USD | 56.543% |
| OncoCyte Corporation | 2.2 Million USD | 71.824% |
| Qualigen Therapeutics, Inc. | - USD | -Infinity% |
| Processa Pharmaceuticals, Inc. | 66.9 Thousand USD | -828.182% |
| Purple Biotech Ltd. | 163 Thousand USD | -280.982% |
| CollPlant Biotechnologies Ltd. | 2.53 Million USD | 75.503% |
| scPharmaceuticals Inc. | 38.81 Million USD | 98.4% |
| ProMIS Neurosciences, Inc. | - USD | -Infinity% |
| HilleVax, Inc. | 25.24 Million USD | 97.54% |
| NeuroSense Therapeutics Ltd. | 73 Thousand USD | -750.685% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | - USD | -Infinity% |
| Neumora Therapeutics, Inc. Common Stock | 1.85 Million USD | 66.487% |
| Atossa Therapeutics, Inc. | - USD | -Infinity% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | - USD | -Infinity% |
| Savara Inc. | 26.34 Million USD | 97.643% |
| Curis, Inc. | 1.48 Million USD | 58.294% |
| Daré Bioscience, Inc. | 3.91 Million USD | 84.133% |
| Carmell Therapeutics Corporation | 697.71 Thousand USD | 10.995% |
| Titan Pharmaceuticals, Inc. | - USD | -Infinity% |
| Achieve Life Sciences, Inc. | 6000.00 USD | -10250.0% |
| BeiGene, Ltd. | 197.61 Million USD | 99.686% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | 31.871% |
| Revolution Medicines, Inc. Warrant | 80.57 Million USD | 99.229% |
| Protagonist Therapeutics, Inc. | - USD | -Infinity% |
| Erasca, Inc. | 51.88 Million USD | 98.803% |
| bluebird bio, Inc. | 224.41 Million USD | 99.723% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 99.895% |
| DBV Technologies S.A. | 4.52 Million USD | 86.279% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Moderna, Inc. | - USD | -Infinity% |
| Vincerx Pharma, Inc. | 1.34 Million USD | 53.657% |
| Fresh Tracks Therapeutics, Inc. | - USD | -Infinity% |
| Molecular Templates, Inc. | 9.74 Million USD | 93.626% |
| Acrivon Therapeutics, Inc. Common Stock | 3.76 Million USD | 83.515% |
| Travere Therapeutics, Inc. | 377.26 Million USD | 99.835% |
| Monte Rosa Therapeutics, Inc. | 42.87 Million USD | 98.552% |
| Spruce Biosciences, Inc. | 1.71 Million USD | 63.832% |
| Celldex Therapeutics, Inc. | 928 Thousand USD | 33.082% |
| Cogent Biosciences, Inc. | 17.46 Million USD | 96.445% |
| MacroGenics, Inc. | 30.19 Million USD | 97.943% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | 17.7 Million USD | 96.492% |
| Prime Medicine, Inc. | 4.35 Million USD | 85.747% |
| Aditxt, Inc. | 1.04 Million USD | 40.388% |
| Adagene Inc. | 13.54 Million USD | 95.414% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 13.73 Million USD | 95.479% |
| Maravai LifeSciences Holdings, Inc. | 518.7 Million USD | 99.88% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 17.09 Million USD | 96.367% |
| SciSparc Ltd. | 24 Thousand USD | -2487.5% |
| Vericel Corporation | 81.85 Million USD | 99.241% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Minerva Neurosciences, Inc. | 82.01 Million USD | 99.243% |
| Generation Bio Co. | 89.77 Million USD | 99.308% |
| Astria Therapeutics, Inc. | - USD | -Infinity% |
| Black Diamond Therapeutics, Inc. | 22.18 Million USD | 97.201% |
| Arcutis Biotherapeutics, Inc. | 201.79 Million USD | 99.692% |
| Invivyd, Inc. | 722 Thousand USD | 13.989% |
| Relay Therapeutics, Inc. | 48.5 Million USD | 98.72% |
| Quoin Pharmaceuticals, Ltd. | 2923.73 USD | -21139.991% |
| Spero Therapeutics, Inc. | 3.82 Million USD | 83.765% |
| Artelo Biosciences, Inc. | 23 Thousand USD | -2600.0% |
| 2seventy bio, Inc. | 244.01 Million USD | 99.746% |
| ADMA Biologics, Inc. | 130.59 Million USD | 99.524% |
| Clene Inc. | 7.15 Million USD | 91.317% |
| Capricor Therapeutics, Inc. | 3.37 Million USD | 81.607% |
| Boundless Bio, Inc. Common Stock | 247.61 Million USD | 99.749% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Recursion Pharmaceuticals, Inc. | 1.1 Million USD | 43.597% |
| Citius Pharmaceuticals, Inc. | 262.86 Thousand USD | -136.243% |
| Contineum Therapeutics, Inc. Class A Common Stock | 192.62 Million USD | 99.678% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | 97.814% |
| ALX Oncology Holdings Inc. | 9.63 Million USD | 93.557% |
| Vir Biotechnology, Inc. | 111.67 Million USD | 99.444% |
| Evaxion Biotech A/S | 8.48 Million USD | 92.684% |
| Ocular Therapeutix, Inc. | 74.92 Million USD | 99.171% |
| Verve Therapeutics, Inc. | 64.71 Million USD | 99.04% |
| Trevena, Inc. | 35.23 Million USD | 98.237% |
| Surrozen, Inc. | 882 Thousand USD | 29.592% |
| Tyra Biosciences, Inc. | 6.21 Million USD | 90.01% |
| Cingulate Inc. | 135.09 Thousand USD | -359.663% |
| Galmed Pharmaceuticals Ltd. | - USD | -Infinity% |
| Unity Biotechnology, Inc. | 23.53 Million USD | 97.362% |
| Tenax Therapeutics, Inc. | - USD | -Infinity% |
| Terns Pharmaceuticals, Inc. | - USD | -Infinity% |
| ACADIA Pharmaceuticals Inc. | 47.8 Million USD | 98.701% |
| Connect Biopharma Holdings Limited | 180 Thousand USD | -245.0% |
| Clearmind Medicine Inc. | - USD | -Infinity% |
| Kronos Bio, Inc. | 25.37 Million USD | 97.553% |
| Bolt Biotherapeutics, Inc. | 17.43 Million USD | 96.439% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Viking Therapeutics, Inc. | 936 Thousand USD | 33.654% |
| Statera Biopharma, Inc. | 11.43 Million USD | 94.567% |
| ImmunityBio, Inc. | 836.95 Million USD | 99.926% |
| Korro Bio, Inc. | 31.21 Million USD | 98.011% |
| Kineta, Inc. | 150 Thousand USD | -314.0% |
| BioVie Inc. | 349.89 Thousand USD | -77.482% |
| Codexis, Inc. | 12.24 Million USD | 94.928% |
| Celularity Inc. | 26.17 Million USD | 97.628% |
| Crinetics Pharmaceuticals, Inc. | 47.55 Million USD | 98.694% |
| Celcuity Inc. | 37.03 Million USD | 98.323% |
| Virax Biolabs Group Limited | 176.34 Thousand USD | -252.151% |
| Cibus, Inc. | 17.67 Million USD | 96.486% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| IN8bio, Inc. | 3.37 Million USD | 81.622% |
| Kodiak Sciences Inc. | 100 Million USD | 99.379% |
| Annexon, Inc. | 29.19 Million USD | 97.873% |
| Adverum Biotechnologies, Inc. | 64.62 Million USD | 99.039% |
| Assembly Biosciences, Inc. | 1.12 Million USD | 44.652% |
| Avalo Therapeutics, Inc. | 2 Million USD | 68.95% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 99.956% |
| Eyenovia, Inc. | 8.95 Million USD | 93.067% |
| Puma Biotechnology, Inc. | 65.65 Million USD | 99.054% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Xilio Therapeutics, Inc. | 8.14 Million USD | 92.373% |
| Arcellx, Inc. | 50.84 Million USD | 98.779% |
| Cardiff Oncology, Inc. | 1.45 Million USD | 57.407% |
| Enanta Pharmaceuticals, Inc. | 21.23 Million USD | 97.076% |
| Regulus Therapeutics Inc. | 1.05 Million USD | 41.137% |
| Moolec Science SA | 99.04 Thousand USD | -526.981% |
| Acumen Pharmaceuticals, Inc. | 27.62 Million USD | 97.752% |
| Geron Corporation | 35.05 Million USD | 98.228% |
| LAVA Therapeutics N.V. | 591 Thousand USD | -5.076% |
| Royalty Pharma plc | 6.13 Billion USD | 99.99% |
| Atea Pharmaceuticals, Inc. | 1.64 Million USD | 62.18% |
| Greenwich LifeSciences, Inc. | - USD | -Infinity% |
| TFF Pharmaceuticals, Inc. | 31.74 Thousand USD | -1856.398% |
| Mersana Therapeutics, Inc. | 23.14 Million USD | 97.317% |
| Humacyte, Inc. | 38.6 Million USD | 98.391% |
| Structure Therapeutics Inc. | 4.01 Million USD | 84.525% |
| 89bio, Inc. | 24.79 Million USD | 97.495% |
| PMV Pharmaceuticals, Inc. | 12.43 Million USD | 95.006% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Genelux Corporation | 1.86 Million USD | 66.72% |
| Trevi Therapeutics, Inc. | 1.03 Million USD | 39.826% |
| Lexicon Pharmaceuticals, Inc. | 99.5 Million USD | 99.376% |
| Notable Labs, Ltd. | 1.52 Million USD | 59.305% |
| Liquidia Corporation | 2.36 Million USD | 73.731% |
| Mustang Bio, Inc. | 1.97 Million USD | 68.605% |
| Immunovant, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 13.73 Million USD | 95.479% |
| Arbutus Biopharma Corporation | 6.95 Million USD | 91.069% |
| DiaMedica Therapeutics Inc. | 317 Thousand USD | -95.899% |
| Vera Therapeutics, Inc. | 49.87 Million USD | 98.755% |
| Acasti Pharma Inc. | - USD | -Infinity% |
| MiNK Therapeutics, Inc. | - USD | -Infinity% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Xenon Pharmaceuticals Inc. | 9.6 Million USD | 93.534% |
| Elevai Labs, Inc. Common Stock | 65.48 Thousand USD | -848.251% |
| NeuroBo Pharmaceuticals, Inc. | 136 Thousand USD | -356.618% |
| Tempest Therapeutics, Inc. | 6.26 Million USD | 90.086% |
| Soleno Therapeutics, Inc. | 130 Thousand USD | -377.692% |
| PepGen Inc. | 17.1 Million USD | 96.368% |
| Moleculin Biotech, Inc. | 474 Thousand USD | -31.013% |
| United Therapeutics Corporation | 300 Million USD | 99.793% |
| Nuvectis Pharma, Inc. | - USD | -Infinity% |
| Solid Biosciences Inc. | 23.94 Million USD | 97.406% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Immuneering Corporation | 4.16 Million USD | 85.082% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | - USD | -Infinity% |
| Belite Bio, Inc | 578 Thousand USD | -7.439% |
| XOMA Corporation | 118.51 Million USD | 99.476% |
| ARS Pharmaceuticals, Inc. | 37 Thousand USD | -1578.378% |
| Bionomics Limited | 117.62 Million USD | 99.472% |
| Apogee Therapeutics, Inc. | 933 Thousand USD | 33.441% |
| Alpha Tau Medical Ltd. | 5.61 Million USD | 88.93% |
| uniQure N.V. | 130.06 Million USD | 99.523% |
| Cassava Sciences, Inc. | - USD | -Infinity% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | 58.59 Million USD | 98.94% |
| Forte Biosciences, Inc. | - USD | -Infinity% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | 686 Thousand USD | 9.475% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| SeaStar Medical Holding Corporation | 4.33 Million USD | 85.681% |
| FibroBiologics, Inc. Common Stock | 1.38 Million USD | 55.162% |
| Altimmune, Inc. | 175 Thousand USD | -254.857% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 99.84% |
| Alpha Tau Medical Ltd. | 5.61 Million USD | 88.93% |
| Compugen Ltd. | 719 Thousand USD | 13.63% |
| Peak Bio, Inc. | - USD | -Infinity% |
| Zevra Therapeutics, Inc. | 5.06 Million USD | 87.742% |
| Benitec Biopharma Inc. | - USD | -Infinity% |
| Spyre Therapeutics, Inc. | 84.55 Million USD | 99.266% |
| NKGen Biotech, Inc. Common Stock | 9.93 Million USD | 93.746% |
| Zura Bio Limited | - USD | -Infinity% |
| PolyPid Ltd. | 6.37 Million USD | 90.265% |
| Aileron Therapeutics, Inc. | 91.41 Million USD | 99.321% |
| NKGen Biotech, Inc. Warrants | 9.93 Million USD | 93.746% |
| Instil Bio, Inc. | 81.42 Million USD | 99.237% |
| argenx SE | 15.35 Million USD | 95.955% |
| Immunome, Inc. | 1.34 Million USD | 53.657% |
| Compass Therapeutics, Inc. | 536 Thousand USD | -15.858% |
| Verona Pharma plc | 48.37 Million USD | 98.716% |
| enGene Holdings Inc. Warrants | 9.21 Million USD | 93.262% |
| Shattuck Labs, Inc. | 3.4 Million USD | 81.767% |
| CervoMed Inc. | - USD | -Infinity% |
| LENZ Therapeutics, Inc. | - USD | -Infinity% |
| Plus Therapeutics, Inc. | 85 Thousand USD | -630.588% |
| Dianthus Therapeutics, Inc. | 168 Thousand USD | -269.643% |
| Moolec Science SA | 99.04 Thousand USD | -526.981% |
| Enveric Biosciences, Inc. | - USD | -Infinity% |
| Inovio Pharmaceuticals, Inc. | 11.03 Million USD | 94.371% |
| AnaptysBio, Inc. | 16.03 Million USD | 96.128% |
| Design Therapeutics, Inc. | 2.33 Million USD | 73.393% |
| Leap Therapeutics, Inc. | - USD | -Infinity% |
| NeurAxis, Inc. | 27.07 Thousand USD | -2193.968% |
| Seelos Therapeutics, Inc. | - USD | -Infinity% |
| Lumos Pharma, Inc. | 6 Million USD | 89.65% |
| Achilles Therapeutics plc | 1.07 Million USD | 42.286% |
| enGene Holdings Inc. Common Stock | 9.21 Million USD | 93.262% |
| 180 Life Sciences Corp. | 19.93 Thousand USD | -3014.968% |
| Opiant Pharmaceuticals, Inc. | 16.74 Million USD | 96.291% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 79.82 Thousand USD | -677.942% |
| ORIC Pharmaceuticals, Inc. | 7461.00 USD | -8223.281% |
| CG Oncology, Inc. Common stock | 13 Thousand USD | -4676.923% |
| Fractyl Health, Inc. Common Stock | 342.48 Million USD | 99.819% |
| Rani Therapeutics Holdings, Inc. | 24.48 Million USD | 97.464% |
| MoonLake Immunotherapeutics | 2.49 Million USD | 75.16% |
| Palisade Bio, Inc. | 90 Thousand USD | -590.0% |
| Tourmaline Bio, Inc. | 194 Thousand USD | -220.103% |
| Beam Therapeutics Inc. | 159.91 Million USD | 99.612% |
| Neurogene Inc. | 13.37 Million USD | 95.356% |
| Mirum Pharmaceuticals, Inc. | 306.42 Million USD | 99.797% |
| AEON Biopharma, Inc. | - USD | -Infinity% |
| Sesen Bio, Inc. | - USD | -Infinity% |
| Enliven Therapeutics, Inc. | - USD | -Infinity% |
| Kiora Pharmaceuticals, Inc. | 59.82 Thousand USD | -938.08% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | 37.9% |
| Taysha Gene Therapies, Inc. | 40.5 Million USD | 98.467% |
| Athira Pharma, Inc. | 1.21 Million USD | 48.973% |
| Vaccinex, Inc. | 26 Thousand USD | -2288.462% |
| HCW Biologics Inc. | 6.3 Million USD | 90.15% |
| XOMA Corporation | 118.51 Million USD | 99.476% |
| Nektar Therapeutics | 112.62 Million USD | 99.449% |
| Arvinas, Inc. | 800 Thousand USD | 22.375% |
| Tevogen Bio Holdings Inc. | 14.45 Million USD | 95.704% |
| Merus N.V. | 10.48 Million USD | 94.079% |
| Omega Therapeutics, Inc. | 14.88 Million USD | 95.828% |
| Quince Therapeutics, Inc. | 13.42 Million USD | 95.376% |
| Rezolute, Inc. | 1.66 Million USD | 62.59% |
| Clene Inc. | 7.15 Million USD | 91.317% |
| Indaptus Therapeutics, Inc. | 73.34 Thousand USD | -746.649% |
| BeyondSpring Inc. | 3.36 Million USD | 81.54% |
| Synlogic, Inc. | 12.49 Million USD | 95.028% |
| Allarity Therapeutics, Inc. | - USD | -Infinity% |
| Phio Pharmaceuticals Corp. | - USD | -Infinity% |
| Peak Bio, Inc. | - USD | -Infinity% |
| Werewolf Therapeutics, Inc. | 32.65 Million USD | 98.098% |
| Krystal Biotech, Inc. | 6.62 Million USD | 90.619% |
| Karyopharm Therapeutics Inc. | 170.91 Million USD | 99.637% |
| SpringWorks Therapeutics, Inc. | 5.99 Million USD | 89.643% |
| Lipella Pharmaceuticals Inc. | 47.37 Thousand USD | -1210.929% |
| MannKind Corporation | 252.15 Million USD | 99.754% |
| Ikena Oncology, Inc. | 7.18 Million USD | 91.351% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 199 Thousand USD | -212.06% |
| Gossamer Bio, Inc. | 197.4 Million USD | 99.685% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | 520 Thousand USD | -19.423% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Legend Biotech Corporation | 281.32 Million USD | 99.779% |
| Mural Oncology plc | 8.91 Million USD | 93.031% |
| Biora Therapeutics, Inc. | 43.73 Million USD | 98.58% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Disc Medicine, Inc. | 1.43 Million USD | 56.755% |
| Champions Oncology, Inc. | 6.09 Million USD | 89.808% |
| REGENXBIO Inc. | 82.22 Million USD | 99.245% |
| Ensysce Biosciences, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | 494 Thousand USD | -25.708% |
| Edgewise Therapeutics, Inc. | 4.43 Million USD | 85.995% |
| Vaxart, Inc. | 2.62 Million USD | 76.325% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | 271.63 Thousand USD | -128.619% |
| Cellectis S.A. | 36.24 Million USD | 98.286% |
| Longeveron Inc. | 1.44 Million USD | 57.113% |
| Repare Therapeutics Inc. | 1.01 Million USD | 38.515% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 99.945% |
| Inozyme Pharma, Inc. | 44.76 Million USD | 98.613% |
| Revolution Medicines, Inc. | 80.57 Million USD | 99.229% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Third Harmonic Bio, Inc. | 3.2 Million USD | 80.642% |
| ArriVent BioPharma, Inc. Common Stock | 177 Thousand USD | -250.847% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 123 Thousand USD | -404.878% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 99.914% |
| Denali Therapeutics Inc. | 44.98 Million USD | 98.619% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Veru Inc. | 12.5 Million USD | 95.034% |
| Corvus Pharmaceuticals, Inc. | - USD | -Infinity% |
| Cingulate Inc. | 135.09 Thousand USD | -359.663% |
| Passage Bio, Inc. | 22.92 Million USD | 97.291% |
| Context Therapeutics Inc. | - USD | -Infinity% |
| Exicure, Inc. | 6.03 Million USD | 89.717% |
| Day One Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oramed Pharmaceuticals Inc. | 647 Thousand USD | 4.019% |
| Scinai Immunotherapeutics Ltd. | 20.16 Million USD | 96.92% |
| Rhythm Pharmaceuticals, Inc. | 490 Thousand USD | -26.735% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | 407.45 Thousand USD | -52.409% |
| Carisma Therapeutics, Inc. | 1.18 Million USD | 47.727% |
| Unicycive Therapeutics, Inc. | 466 Thousand USD | -33.262% |
| OmniAb, Inc. | 22.07 Million USD | 97.187% |
| Anew Medical, Inc. | 1.54 Million USD | 59.675% |
| Fennec Pharmaceuticals Inc. | 29.55 Million USD | 97.899% |
| Lipocine Inc. | - USD | -Infinity% |
| Lexeo Therapeutics, Inc. Common Stock | 9.03 Million USD | 93.125% |
| Nautilus Biotechnology, Inc. | 31.09 Million USD | 98.003% |
| SAB Biotherapeutics, Inc. | 4.05 Million USD | 84.683% |
| G1 Therapeutics, Inc. | 51.55 Million USD | 98.796% |
| Bellerophon Therapeutics, Inc. | - USD | -Infinity% |
| Sage Therapeutics, Inc. | - USD | -Infinity% |
| Ocugen, Inc. | 6.36 Million USD | 90.247% |
| Mind Medicine (MindMed) Inc. | 14.12 Million USD | 95.605% |
| Q32 Bio Inc. | - USD | -Infinity% |
| Brainstorm Cell Therapeutics Inc. | 672 Thousand USD | 7.589% |
| Alumis Inc. Common Stock | 30.86 Million USD | 97.988% |
| Equillium, Inc. | 384 Thousand USD | -61.719% |
| Kyverna Therapeutics, Inc. | 6.15 Million USD | 89.917% |
| Coya Therapeutics, Inc. | - USD | -Infinity% |
| CNS Pharmaceuticals, Inc. | - USD | -Infinity% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 99.589% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 98.73% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -416.201% |
| Dominari Holdings Inc. | 3.02 Million USD | 79.491% |
| Edesa Biotech, Inc. | 19.77 Thousand USD | -3040.646% |
| vTv Therapeutics Inc. | 169 Thousand USD | -267.456% |
| Bio-Techne Corporation | 319 Million USD | 99.805% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 98.91% |
| Harmony Biosciences Holdings, Inc. | 178.56 Million USD | 99.652% |
| Prelude Therapeutics Incorporated | 15.4 Million USD | 95.969% |
| Candel Therapeutics, Inc. | 12.38 Million USD | 94.985% |
| iTeos Therapeutics, Inc. | 4.8 Million USD | 87.081% |
| Nkarta, Inc. | 82.27 Million USD | 99.245% |
| BioCardia, Inc. | 982 Thousand USD | 36.762% |
| Iterum Therapeutics plc | 18.95 Million USD | 96.724% |